Australian first prostate biopsy technology launches at Pindara


Pindara Private Hospital is leading Australia, becoming the first hospital to implement the Artemis transperineal system.

The system, which is only available in a few places around the world, uses the latest technology and software to increase ease and safety of prostate biopsies for more accurate results for patients.

One-in-five men will be diagnosed with prostate cancer by the age of 85 and it is the third most common cause of cancer death in Australia, according to the Australian Cancer Council, making improved diagnosis a matter of life or death for Australian men.

Gold Coast urologist Dr Charles Chabert said the system uses innovative robotic and MRI technology, combined with the latest transperineal surgical approach to produce safer and more precise biopsies.

A transperineal biopsy has the potential benefit of providing better access to the anterior surface. This is an area which can be difficult to target with a traditional transrectal approach. Avoiding needle placement through the bowel wall also reduces infection risk.

"It’s pleasing to see this world-class technology now available to benefit patients at Pindara Private Hospital," said Dr Chabert.

The first global application of the Artemis transperineal system was in Switzerland, which was quickly followed by Pindara Private Hospital completing a four month trial of the technology in 2016.

Urologists at Pindara started treating patients with this new technology at the end of February.

The hospital will also be a reference site for other urologists interested in learning more about this new technology.


The Artemis platform

The Artemis platform is the only system available that is based on a combination of 3D semi-robotic tracking and deformable MR-Ultrasound fusion.

It uses a mechanical robotic arm to stabilise and hold the ultrasound probe and track it continuously in 3D. This eliminates the deformation of the prostate during the biopsy procedure and leads to accurate and reproducible biopsy targeting.

Artemis' motion compensation feature allows real time correction for intra-procedure prostate motion. In addition, all biopsies that are taken are recorded on a 3D map which allows the urologist to know exactly where a patient’s disease might be located so that if they were to be managed with active surveillance they would have a precise map of where to monitor in the future. Once again, removing the guess work.


Comments are closed.